| Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc |
| Journal website https://jmc.elmerpub.com |
Case Report
Volume 17, Number 6, June 2026, pages 280-284
Relapsed Immune Thrombocytopenic Purpura Following COVID-19 Vaccination in a Patient With Autoimmune Cytopenias
Table
| Study | Age/sex | Vaccine type | Time of onset | Prior ITP/autoimmunity | Treatment | Outcome |
|---|---|---|---|---|---|---|
| Time of onset refers to the interval between vaccination and onset of thrombocytopenia. Outcomes reflect platelet recovery or clinical response as reported in the original studies. SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; F: female; M: male; IVIG: intravenous immunoglobulin; ITP: immune thrombocytopenic purpura. | ||||||
| Lee et al, 2021 [7] | 72/F | Pfizer | 5 days | No | IVIG and steroids | Platelet recovery |
| Welsh et al 2021, [6] | 65/M | Moderna | 10 days | No | IVIG and steroids | Improved |
| Lee et al, 2022 [9] | 68/M | Pfizer | 7 days | Yes (ITP) | IVIG and steroids | Relapsed, required retreatment |
| Tarawneh et al, 2021 [10] | 22/F | Pfizer | 14 days | No | IVIG and steroids | Recovered |
| Chong et al, 2021 [11] | 75/M | Moderna | 3 days | Yes (autoimmune disease) | IVIG and steroids | Partial response |